HD5 TFA |
|
Catalog No.GC78912
|
HD5 TFA is an innate immune effector peptide and SARS-CoV Inhibitor.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
In Vivo, HD5 (ectopic expression via lentiviral transduction; ~47 pg/mL secreted in cell supernatants) TFA significantly inhibits the oncolytic activity of PtDd-deficient adenoviruses (mut-Ad3GFP, wt-Ad5GFP) but not PtDd-producing adenovirus (wt-Ad3GFP) in CB17 mice subcutaneously injected with K562-HD5 cells, with PtDd able to reverse HD5-mediated inhibition of mut-Ad3GFP[3].
In Vitro, HD5 TFA binds with high affinity to the ligand-binding domain of host cell ACE2, competitively blocking and shielding the receptor to prevent SARS-CoV-2 recognition and infection of host cells[1]. HD5 (20 µM) TFA binds to regions of HPV16 L1 and L2 capsid proteins[2]. HD5 (15 μM; 5 days) TFA significantly inhibits the spread and cytolytic activity of PtDd-deficient mut-Ad3GFP in A549 cells, while only minimally impacting PtDd-producing wt-Ad3GFP[3]. HD5 (0.1 μM) TFA binds to HAdV3 penton base, fiber, fiber knob, and multimeric penton base-containing structures (PtDd and virion-associated penton bases) in a Western blot assay[3]. HD5 TFA significantly inhibits progeny virus production and spread of PtDd-deficient mut-Ad3GFP in Caco-2 and T84 cells, while PtDd-producing wt-Ad3GFP is unaffected[3].
References:
[1]. Mahendran ASK, et al. The Potential of Antiviral Peptides as COVID-19 Therapeutics. Front Pharmacol. 2020 Sep 15;11:575444. doi: 10.3389/fphar.2020.575444.
[2]. Gulati NM, et al. α-Defensin HD5 Stabilizes Human Papillomavirus 16 Capsid/Core Interactions. Pathog Immun. 2019 Sep 12;4(2):196-234.
[3]. Vragniau C, et al. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol. 2017;91(6):e02030-16. Published 2017 Feb 28.
| Cas No. | SDF | ||
| Formula | C144H238N50O45S6·xC2HF3O2 | M.Wt | 3582.13 |
| Solubility | H2O: ≥ 100 mg/mL | Storage | Sealed storage, away from moisture |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 279.2 μL | 1.3958 mL | 2.7916 mL |
| 5 mM | 55.8 μL | 279.2 μL | 558.3 μL |
| 10 mM | 27.9 μL | 139.6 μL | 279.2 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















